Research Paper Volume 13, Issue 10 pp 14078—14087

Figure 4. MiR-588 is able to target CXCR4 in LSCC cells. (A) The interaction of miR-588 and CXCR4 3′UTR was identified by bioinformatic analysis using Targetscan (http://www.targetscan.org/vert_72/). (B–D) The AMC-HN-8 and Hep-2 cells were treated with the miR-588 mimic or control mimic. (B) The luciferase activities of wild type CXCR4 (WT) and CXCR4 with the miR-588-binding site mutant (MUT) were determined by luciferase reporter gene assays in the cell. (C) The mRNA expression of CXCR4 was analyzed by qPCR in the cells. (D) The protein expression of CXCR4 and β-actin was tested by Western blot analysis in the cells. (E) The AMC-HN-8 and Hep-2 cells were treated control shRNA, circABCB10 shRNA, or co-treated with circABCB10 shRNA and miR-588 inhibitor. The protein expression of CXCR4 and β-actin was assessed by Western blot analysis in the cells. Data are presented as mean ± SD. Statistic significant differences were indicated: ^**P < 0.01.